May 01, 2026 a 05:00 pm
ZBH: Analysts Ratings - Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. shows a mixed sentiment among analysts as of May 2026, with a cautious stance prevalent. The orthopedic reconstructive products company experienced a shift towards more "Hold" ratings in recent months. While the business remains robust, transformation and adaptation in its market sectors are crucial to capturing analysts' favor. Investors should monitor evolving trends and evaluate potential long-term growth prospects.
Historical Stock Grades
| Rating Type | Number | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 6 | |
| Hold | 17 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, there has been a noticeable increase in "Hold" ratings, suggesting a more cautious approach by analysts. This shift, coupled with decreased "Strong Buy" recommendations and steady "Buy" ratings, may indicate a balanced perspective with limited immediate buy interest.
- The total number of ratings peaked towards mid-2025 and remained stable thereafter.
- Strong Buy ratings reduced from a high of 13 to a low point of 2 in May 2026.
- Hold ratings saw a consistent rise, peaking at 19, reflecting a more cautious analyst sentiment.
Percentage Trends
The change in analyst sentiments is evident as "Strong Buy" ratings significantly decreased, while "Hold" ratings experienced an uptrend. This portrays a shift towards conservatism and market ambivalence.
- The proportion of Hold ratings currently sits at a high 70%.
- Strong Buy ratings, having been nearly 50% in early 2024, descended swiftly.
- The growing neutrality is apparent as analysts prefer to "Hold" rather than take a stance on buying.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-29 | Neutral | Neutral | JP Morgan |
| 2026-04-29 | Market Outperform | Market Outperform | Citizens |
| 2026-04-29 | Buy | Buy | Stifel |
| 2026-04-29 | Equal Weight | Equal Weight | Wells Fargo |
| 2026-04-29 | Hold | Hold | Truist Securities |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-23 | Neutral | Buy | BTIG |
| 2026-01-05 | Outperform | In Line | Evercore ISI Group |
| 2025-12-16 | Neutral | Outperform | Baird |
| 2025-11-06 | Neutral | Overweight | JP Morgan |
| 2024-12-17 | Overweight | Neutral | JP Morgan |
Interpretation
Current analysis indicates a trend towards cautious neutrality among analysts for Zimmer Biomet Holdings, Inc. This viewpoint reflects potential market uncertainties or a reevaluation of growth potential. With the reduction in "Strong Buy" ratings, skepticism appears to be on the rise. However, stabilization in the "Neutral" and "Hold" categories points to continued but guarded interest in the stock.
Conclusion
Zimmer Biomet Holdings, Inc. faces both potential and challenges. While market expansion in musculoskeletal healthcare offers growth opportunities, the increase in neutral analyst ratings suggests a wait-and-see approach. Analysts are keenly observant of economic conditions surrounding the company. Increasing Hold recommendations may indicate restrained optimism due to competitive pressures or market dynamics. Investors should remain vigilant, observing both external conditions and company-specific actions that could alter analyst perspectives in the months to come.